Home > Insider Trading > Filing (0001209191-20-063474)

Filing Details

Accession Number:: 0001209191-20-063474
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-12-15 16:24:34
Reporting Period:: 2020-12-11

Accepted Time:: 2020-12-15 16:24:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1347178	Vanda Pharmaceuticals Inc.	VNDA	Pharmaceutical Preparations (2834)	030491827

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1355537	Hristos Mihael Polymeropoulos	2200 Pennsylvania Avenue Suite 300E Washington DC 20037	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-12-11	41,817	$8.75	1,320,816	No	4	M	Direct
Common Stock	Disposition	2020-12-11	35,053	$12.88	1,285,763	No	4	S	Direct
Common Stock	Acquisiton	2020-12-14	61,520	$8.75	1,347,283	No	4	M	Direct
Common Stock	Disposition	2020-12-14	51,049	$13.19	1,296,234	No	4	S	Direct
Common Stock	Acquisiton	2020-12-15	46,663	$8.75	1,342,897	No	4	M	Direct
Common Stock	Disposition	2020-12-15	39,150	$13.00	1,303,747	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2020-12-11	41,817	$0.00	41,817	$8.75
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2020-12-14	61,520	$0.00	61,520	$8.75
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2020-12-15	46,663	$0.00	46,663	$8.75

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
108,183	2020-12-15	No	4	M	Direct
46,663	2020-12-15	No	4	M	Direct
0	2020-12-15	No	4	M	Direct

Footnotes

Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 15, 2020 as reflected in this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.85 to $13.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
The option vested in 48 equal monthly installments from the date of grant.